Is RAPP a good stock to buy?
We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro’s Substack
In this article, we will summarize the bulls’ thesis on RAPP. Rapport Therapeutics, Inc.’s share was trading at $38.26 as of June 15th. RAPP’s trailing P/E was 23.78 according to Yahoo Finance.
Pressmaster/ Rapport Therapeutics (RAPP) is a Boston-based clinical-stage biotechnology company developing precision therapies for serious neurological and psychiatric disorders, with its lead candidate RAP-219 targeting receptor-associated proteins (RAPs) that regulate neuronal signaling through a differentiated mechanism aimed at addressing the limitations of conventional symptomatic epilepsy treatments. 15 AI Stocks That Are Quietly Making Investors Rich Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential The investment case is increasingly defined by strong clinical momentum as RAP-219 delivered standout efficacy in Phase 2a trials for drug-resistant focal onset epilepsy, with follow-up data presented at the 2026 American Academy of Neurology meeting indicating sustained therapeutic benefit well beyond the active dosing period, a rare and highly encouraging signal in central nervous system drug development. Building on this foundation, the company is now advancing RAP-219 into Phase 3 trials, marking entry into the most critical stage before potential regulatory approval and commercialization. At the same time, Rapport is broadening its pipeline into additional high-value indications, including bipolar mania and diabetic peripheral neuropathic pain, significantly expanding its total addressable market and strengthening long-term optionality.